Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.67 |
| ▸ | MEN1 | O00255 | 2/20 | 0.67 |
| ▸ | MAPT | P10636 | 6/20 | 0.54 |
| ▸ | RECQL | P46063 | 1/20 | 0.48 |
| ▸ | JMJD6 | Q6NYC1 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 3/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.45 |
| ▸ | HTT | P42858 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | PTBP1 | P26599 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 3/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.43 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4468900 | 0.84 | RECQL (0.53) | KMT2AMEN1MAPTRECQLJMJD6 | |
| SCHEMBL13919666 | 0.82 | KMT2A (0.43) | KMT2AMEN1MAPTGAANPC1 | |
| SCHEMBL9879486 | 0.80 | KMT2A (1.00) | KMT2AMEN1MAPTRECQLJMJD6 | |
| SCHEMBL5923138 | 0.77 | RECQL (0.46) | KMT2AMEN1MAPTRECQLNPC1 | |
| Ditolylguanidine SCHEMBL35348 | 0.74 | NPC1 (0.61) | KMT2AMEN1NPC1HTTALDH1A1 | |
| Ditolylguanidine SCHEMBL30468948 | 0.74 | NPC1 (0.61) | KMT2AMEN1NPC1HTTALDH1A1 | |
| Ditolylguanidine SCHEMBL5608944 | 0.73 | NPC1 (0.59) | KMT2AMEN1NPC1HTTALDH1A1 | |
| Ditolylguanidine SCHEMBL34468120 | 0.73 | NPC1 (0.59) | KMT2AMEN1NPC1HTTALDH1A1 | |
| Ditolylguanidine SCHEMBL28288690 | 0.73 | NPC1 (0.59) | KMT2AMEN1MAPTNPC1HTT | |
| SCHEMBL4471243 | 0.72 | MEN1 (0.53) | KMT2AMEN1MAPTRECQLJMJD6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7504502-B2 | Guanidinopyrimidinone compounds and phase change inks containing same | XEROX CORPORATION (US) | 2009-03-17 | — | — | US | disclosed |
| US-20080171877-A1 | GUANIDINOPYRIMIDINONE COMPOUNDS AND PHASE CHANGE INKS CONTAINING SAME | XEROX CORPORATION (US) | 2008-07-17 | — | — | US | disclosed |
| US-7371858-B2 | Guanidinopyrimidinone compounds and phase change inks containing same | XEROX CORPORATION (US) | 2008-05-13 | — | — | US | disclosed |
| US-20060149063-A1 | Guanidinopyrimidinone compounds and phase change inks containing same | XEROX CORPORATION | 2006-07-06 | — | — | US | disclosed |
| US-6811595-B2 | Guanidinopyrimidinone compounds and phase change inks containing same | XEROX CORPORATION | 2004-11-02 | — | — | US | disclosed |
| US-20040060474-A1 | Guanidinopyrimidinone compounds and phase change inks containing same | XEROX CORPORATION | 2004-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060149063-A1 | Guanidinopyrimidinone compounds and phase change inks containing same | RPP30, INO80, CDK20 | KMT2A 2305/4885MEN1 4220/4885MAPT 4002/4885 |
| US-20040060474-A1 | Guanidinopyrimidinone compounds and phase change inks containing same | CCNI, INO80, CCNY | KMT2A 1779/4885MEN1 4310/4885MAPT 3797/4885 |
| US-20080171877-A1 | GUANIDINOPYRIMIDINONE COMPOUNDS AND PHASE CHANGE INKS CONTAINING SAME | INO80, RPP30, RO60 | KMT2A 1968/4885MEN1 4021/4885MAPT 3723/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.